CA2177696C - Lipid vesicles containing avocado oil unsaponifiables - Google Patents
Lipid vesicles containing avocado oil unsaponifiables Download PDFInfo
- Publication number
- CA2177696C CA2177696C CA002177696A CA2177696A CA2177696C CA 2177696 C CA2177696 C CA 2177696C CA 002177696 A CA002177696 A CA 002177696A CA 2177696 A CA2177696 A CA 2177696A CA 2177696 C CA2177696 C CA 2177696C
- Authority
- CA
- Canada
- Prior art keywords
- polyoxyethylene
- group
- bilayers
- amphiphile
- phospholipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000002632 lipids Chemical class 0.000 title claims abstract description 118
- 235000021302 avocado oil Nutrition 0.000 title claims abstract description 79
- 239000008163 avocado oil Substances 0.000 title claims abstract description 79
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 47
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 claims abstract description 46
- 238000000034 method Methods 0.000 claims abstract description 25
- 239000003921 oil Substances 0.000 claims abstract description 22
- 235000019198 oils Nutrition 0.000 claims abstract description 22
- 238000004519 manufacturing process Methods 0.000 claims abstract description 5
- -1 polyoxyethylene Polymers 0.000 claims description 123
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 70
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 36
- 239000000194 fatty acid Substances 0.000 claims description 36
- 229930195729 fatty acid Natural products 0.000 claims description 36
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 34
- 239000012071 phase Substances 0.000 claims description 30
- 239000000232 Lipid Bilayer Substances 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 28
- 239000000463 material Substances 0.000 claims description 25
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 22
- 239000008346 aqueous phase Substances 0.000 claims description 18
- 150000002191 fatty alcohols Chemical class 0.000 claims description 16
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 14
- 125000002252 acyl group Chemical group 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 11
- 150000002194 fatty esters Chemical class 0.000 claims description 10
- 125000006353 oxyethylene group Chemical group 0.000 claims description 10
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 8
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 8
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 8
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Chemical group CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 7
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Chemical group CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 7
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Chemical group CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 7
- 239000005642 Oleic acid Chemical group 0.000 claims description 7
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Chemical group CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 7
- 235000021355 Stearic acid Nutrition 0.000 claims description 7
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 claims description 7
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 claims description 7
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Chemical group CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 7
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 7
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical group CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 7
- 239000008117 stearic acid Chemical group 0.000 claims description 7
- OQQOAWVKVDAJOI-UHFFFAOYSA-N (2-dodecanoyloxy-3-hydroxypropyl) dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCC OQQOAWVKVDAJOI-UHFFFAOYSA-N 0.000 claims description 6
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 claims description 6
- 229940074049 glyceryl dilaurate Drugs 0.000 claims description 6
- 230000000887 hydrating effect Effects 0.000 claims description 6
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 claims description 5
- 150000001412 amines Chemical class 0.000 claims description 5
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 229930186217 Glycolipid Natural products 0.000 claims description 4
- FOLJTMYCYXSPFQ-CJKAUBRRSA-N [(2r,3s,4s,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-(octadecanoyloxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl octadecanoate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)O[C@@H]1O[C@@]1(COC(=O)CCCCCCCCCCCCCCCCC)[C@@H](O)[C@H](O)[C@@H](CO)O1 FOLJTMYCYXSPFQ-CJKAUBRRSA-N 0.000 claims description 4
- 125000000129 anionic group Chemical group 0.000 claims description 4
- 150000005690 diesters Chemical class 0.000 claims description 4
- 150000004665 fatty acids Chemical class 0.000 claims description 4
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 4
- 229920000059 polyethylene glycol stearate Polymers 0.000 claims description 4
- 229920000223 polyglycerol Chemical class 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 239000002195 soluble material Substances 0.000 claims description 3
- 238000005192 partition Methods 0.000 claims description 2
- 238000000638 solvent extraction Methods 0.000 claims description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical group CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims 12
- AOHAPDDBNAPPIN-UHFFFAOYSA-N 3-Methoxy-4,5-methylenedioxybenzoic acid Chemical group COC1=CC(C(O)=O)=CC2=C1OCO2 AOHAPDDBNAPPIN-UHFFFAOYSA-N 0.000 claims 6
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims 6
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims 6
- 239000002253 acid Substances 0.000 claims 5
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 claims 3
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims 3
- 239000005639 Lauric acid Substances 0.000 claims 3
- 235000021360 Myristic acid Nutrition 0.000 claims 3
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims 3
- 150000007513 acids Chemical class 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- DCAYPVUWAIABOU-UHFFFAOYSA-N alpha-n-hexadecene Chemical group CCCCCCCCCCCCCCCC DCAYPVUWAIABOU-UHFFFAOYSA-N 0.000 claims 3
- 125000005313 fatty acid group Chemical group 0.000 claims 3
- 229960002442 glucosamine Drugs 0.000 claims 3
- 229940100242 glycol stearate Drugs 0.000 claims 3
- 235000020778 linoleic acid Nutrition 0.000 claims 3
- OYHQOLUKZRVURQ-HZJYTTRNSA-N linoleic acid group Chemical group C(CCCCCCC\C=C/C\C=C/CCCCC)(=O)O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical group CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims 3
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims 2
- 235000021314 Palmitic acid Nutrition 0.000 claims 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims 1
- 239000002537 cosmetic Substances 0.000 abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 20
- 239000002245 particle Substances 0.000 description 15
- 238000005119 centrifugation Methods 0.000 description 13
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 12
- 238000000926 separation method Methods 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 235000012000 cholesterol Nutrition 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 10
- 239000012530 fluid Substances 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 239000002502 liposome Substances 0.000 description 8
- 230000003020 moisturizing effect Effects 0.000 description 8
- 150000003626 triacylglycerols Chemical class 0.000 description 8
- 229920001214 Polysorbate 60 Polymers 0.000 description 7
- 229940073669 ceteareth 20 Drugs 0.000 description 7
- 230000036571 hydration Effects 0.000 description 7
- 238000006703 hydration reaction Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000004166 Lanolin Substances 0.000 description 6
- PCJBWDWEHOEPFA-UHFFFAOYSA-N O(C1=CC=CC=C1)C(=C)O.C(CC(CBr)(C#N)Br)C#N Chemical compound O(C1=CC=CC=C1)C(=C)O.C(CC(CBr)(C#N)Br)C#N PCJBWDWEHOEPFA-UHFFFAOYSA-N 0.000 description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- 229940074045 glyceryl distearate Drugs 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 229940039717 lanolin Drugs 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 229920000289 Polyquaternium Polymers 0.000 description 5
- 229920000053 polysorbate 80 Polymers 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- HNUQMTZUNUBOLQ-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-(2-octadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO HNUQMTZUNUBOLQ-UHFFFAOYSA-N 0.000 description 4
- 244000027321 Lychnis chalcedonica Species 0.000 description 4
- 239000004909 Moisturizer Substances 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 229940075507 glyceryl monostearate Drugs 0.000 description 4
- 235000019388 lanolin Nutrition 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 230000001333 moisturizer Effects 0.000 description 4
- LSTDYDRCKUBPDI-UHFFFAOYSA-N palmityl acetate Chemical compound CCCCCCCCCCCCCCCCOC(C)=O LSTDYDRCKUBPDI-UHFFFAOYSA-N 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 4
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 4
- 229940113124 polysorbate 60 Drugs 0.000 description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 244000147568 Laurus nobilis Species 0.000 description 3
- 235000017858 Laurus nobilis Nutrition 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 235000005212 Terminalia tomentosa Nutrition 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 229940000033 dermatological agent Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 2
- HBXWUCXDUUJDRB-UHFFFAOYSA-N 1-octadecoxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCC HBXWUCXDUUJDRB-UHFFFAOYSA-N 0.000 description 2
- NMSBTWLFBGNKON-UHFFFAOYSA-N 2-(2-hexadecoxyethoxy)ethanol Chemical compound CCCCCCCCCCCCCCCCOCCOCCO NMSBTWLFBGNKON-UHFFFAOYSA-N 0.000 description 2
- MGYUQZIGNZFZJS-KTKRTIGZSA-N 2-[2-[(z)-octadec-9-enoxy]ethoxy]ethanol Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCOCCO MGYUQZIGNZFZJS-KTKRTIGZSA-N 0.000 description 2
- GLCFQKXOQDQJFZ-UHFFFAOYSA-N 2-ethylhexyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCC(CC)CCCC GLCFQKXOQDQJFZ-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- LVDKZNITIUWNER-UHFFFAOYSA-N Bronopol Chemical compound OCC(Br)(CO)[N+]([O-])=O LVDKZNITIUWNER-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 229960003168 bronopol Drugs 0.000 description 2
- 229940081733 cetearyl alcohol Drugs 0.000 description 2
- 229940049297 cetyl acetate Drugs 0.000 description 2
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- REZZEXDLIUJMMS-UHFFFAOYSA-M dimethyldioctadecylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC REZZEXDLIUJMMS-UHFFFAOYSA-M 0.000 description 2
- 229940073551 distearyldimonium chloride Drugs 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 150000002195 fatty ethers Chemical class 0.000 description 2
- 230000009969 flowable effect Effects 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- UHUSDOQQWJGJQS-UHFFFAOYSA-N glycerol 1,2-dioctadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCCCCCCCC UHUSDOQQWJGJQS-UHFFFAOYSA-N 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 229940055577 oleyl alcohol Drugs 0.000 description 2
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 230000003716 rejuvenation Effects 0.000 description 2
- 229940069764 shark liver oil Drugs 0.000 description 2
- 239000010686 shark liver oil Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 1
- NLMKTBGFQGKQEV-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hexadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO NLMKTBGFQGKQEV-UHFFFAOYSA-N 0.000 description 1
- JKXYOQDLERSFPT-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-octadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO JKXYOQDLERSFPT-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 244000144927 Aloe barbadensis Species 0.000 description 1
- 235000002961 Aloe barbadensis Nutrition 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 244000025272 Persea americana Species 0.000 description 1
- 235000008673 Persea americana Nutrition 0.000 description 1
- 244000264897 Persea americana var. americana Species 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229940026215 c12-15 alkyl lactate Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- RNPXCFINMKSQPQ-UHFFFAOYSA-N dicetyl hydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(=O)OCCCCCCCCCCCCCCCC RNPXCFINMKSQPQ-UHFFFAOYSA-N 0.000 description 1
- 229940093541 dicetylphosphate Drugs 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- ILRSCQWREDREME-UHFFFAOYSA-N dodecanamide Chemical compound CCCCCCCCCCCC(N)=O ILRSCQWREDREME-UHFFFAOYSA-N 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000021474 generally recognized As safe (food) Nutrition 0.000 description 1
- 235000021473 generally recognized as safe (food ingredients) Nutrition 0.000 description 1
- 150000002313 glycerolipids Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- SXQFCVDSOLSHOQ-UHFFFAOYSA-N lactamide Chemical compound CC(O)C(N)=O SXQFCVDSOLSHOQ-UHFFFAOYSA-N 0.000 description 1
- 239000008206 lipophilic material Substances 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000002884 skin cream Substances 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 239000002691 unilamellar liposome Substances 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/12—Preparations containing hair conditioners
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Fats And Perfumes (AREA)
Abstract
Disclosed are oil-filled paucilamellar lipid vesicles containing at least one non-phospholipid amphiphile as the primary lipid of the vesicle bilayers and avocado oil unsaponifiables. The vesicles are particularly useful for delivering dermatological, cosmetic and pharmaceutical formulations. A method of manufacture for these vesicles is also disclosed.
Description
,W0 95/16436 ~ ~ ~ ~ PCT/US94/12158 LIPID VESICLES CONTAINING AVOCADO OIL UNSAPONIFIABLES
The present invention relates to formulations for lipid vesicles and methods of their manufacture. More particularly, the present invention discloses paucimellar lipid vesicles designed of materials which have exceptional properties for cosmetic, edible, dermatological, and pharmaceutical use. The paucimellar vesicles have 2-10 lipid bilayers surrounding a large, amorphous central cavity which contains a water-immiscible oily material including triglycerides supplied by avocado oil unsaponifiables. The lipid bilayers of these vesicles contain at least one non-phospholipid amphiphile as the primary structural material of the lipid bilayers, along with phytosterol from avocado oil unsaponifiables which acts as a membrane or bilayer modulator.
Lipid vesicles are substantially spherical structures made of amphiphiles, e.g., surfactants or phospholipids. The lipids of these spherical vesicles are generally organized in the form of lipid bilayers, e.g., multiple onion-like shells of lipid bilayers which encompass an aqueous volume between the bilayers. Paucilamellar lipid vesicles have 2-10 peripheral bilayers which surround a large, unstructured central cavity.
Until recently, liposome technology has been concerned mostly with vesicles composed of phospholipids. This is primarily because phospholipids are the principal structural components of natural membranes and, accordingly, lipid vesicles have been used as a model system for studying natural membranes. However, there are a number of problems associated with using phospholipids as synthetic membranes.
Biological membranes are stabilized by membrane proteins and maintained by extensive enzymatic "support" systems that rapidly tum over, exchange or modify membrane lipids.
Neither membrane proteins nor the requisite enzymatic support systems can be practically incorporated into the wall structure of liposomes, making the structures inherently less stable than natural membranes. In addition, the biological environment contains several potent phospholipases that rapidly break down free phospholipids. These phospholipids will attack liposomes and degrade the membrane. For these reasons, phospholipid liposomes placed in an in vivo environment are rapidly degraded.
Moreover, phospholipid liposome technology has other problems. Phospholipids are labile and expensive to purify or synthesize. In addition, classic phospholipid liposomes are in the form of multilamellar as opposed to paucilamellar vesicles and have poor carrying capacities, especially for lipophilic materials, and have poor shelf lives unless lyophilized in the dark with antioxidants. While unilamellar vesicles (these only having one bilayer) add additional carrying capacity. they are much less stable. Finally, phospholipids degrade too rapidly in_ viv for most pharmaceutical or vaccine applications.
. For these reasons, there is increasing interest in liposomes made of commercially available nonphospholipid amphiphiles (see, e.g., U.S. Pat. No. 4,217,344, U.S
Pat. No.
4,917,951, and U.S. Pat. No. 4,911,928). These molecules have a hydrophilic "head" group attached to a hydrophobic "tail" and are derived from long chain fatty acids, long chain alcohols and their derivatives, long chain amines, and polyol sphingo- and glycerolipids.
Commercially available amphiphile surfactants include, for example, the BRIJ~
family of polyoxyethylene fatty ethers, the SPAN sorbitan fatty acid esters, the TWEEN'ethoxylated sorbitan fatty acid esters, glyceryl monostearate, glyceryl distearate, and glyceryl dilaurate, all available from ICI Americas, Inc. of Wilmington, De.
Paucilamellar vesicles comprised of such non-phospholipid amphiphiles provide a number of advantages over classical phospholipid multilamellar liposomes. For instance.
these vesicles have a high carrying capacity for water-soluble and water immiscible substances. Also, the amphiphiles used to make up the vesicle bilayers can often be used as emulsifiers or thickeners, providing the "feel" to certain cosmetics and/or dermatologicals.
Furthermore, many of these amphiphiles fall under the GRAS list of edible materials and therefore can be used in many food and pharmaceutical products.
It has previously been shown that when forming lipid vesicles containing at least one amphiphile as the primary lipid of the bilayers, the addition of a membrane modulator considerably improves the shape and size of lipid vesicles, as well as the consistency of the formulation after processing (See e.g., U.S. Patent No. 5,260,065). In the past, cholesterol has generally been used for this purpose. Sterols such as cholesterol also act to modify the thermotropic phase transition of the amphiphiles. However, cholesterol has the drawback of being an undesirable ingredient for use in most edible and pharmaceutical preparations.
Avocado oil unsaponifiables (a source of phytosterol) can be used instead of cholesterol as a bilayer modulator and provides many cosmetic, dermatological and pharmaceutical benefits. For example, it has a soft waxy consistency that confers a creamy texture to skin care products in addition to its moisturizing effects. Avocado oil unsaponifiables are also non-cytoxic, non-irritating and edible.
Accordingly, an object of the present invention is to provide a method of making paucimellar lipid vesicles using materials which are edible and/or have cosmetic, dermatological and pharmaceutical benefits.
'Trade-murk Another object of the invention is to provide paucilamellar lipid vesicles which contain a blend of at least one non-phospholipid amphiphile as the primary structural material of the bilayers and phytosterol supplied by avocado oil unsaponifiables as a modulator.
A further object of the invention is to provide a method of producing paucimellar lipid vesicles which readily encapsulate water immiscible oily materials and are manufactured from relatively inexpensive materials.
These and other objects and features of the invention will be apparent from the following description and the claims.
Summary of the Invention The present invention features paucilamellar lipid vesicles having 2-10 bilayers 1 ~ surrounding an amorphous central cavity which is substantially filled with an oily material.
The lipid bilayers contain at least one non-phospholipid amphiphile as the primary lipid and phvtosterol supplied by avocado oil unsaponifiables as a modulator. The lipid bilayers may further contain a negative charge producing agent, such as dicetyl phosphate, oleic acid, stearic acid, or mixtures thereof or a positive charge producing agent, such as quaternary ammonium compounds. The term "primary lipid", as used herein, means that this lipid is the major lipid, by weight, forming the structure of the lipid bilayers.
In a preferred embodiment, the primary non-phospholipid amphiphile is selected from the group consisting of polyoxyethylene fatty esters, polyoxyethylene fatty acid ethers, diethanolamides, long chain acyl hexosamides, long chain acyl amino acid amides, long chain acyl amides, polyoxyethylene derivatives of fatty acid esters having 10-20 oxyethylene groups, polyoxyethylene 20 sorbitan mono- or trioletate, polyoxyethylene glyceryl monostearate with 1-10 oxyethylene groups, and glycerol monostearate. In another preferred embodiment, the bilayers further contain a phospholipid, a glycolipid, and mixtures thereof.
In yet another preferred embodiment, the primary non-phospholipid amphiphile is selected from the group consisting of betaines and anionic sarcosinamides.
In still another preferred embodiment, the bilayers contain both a primary non-phospholipid amphiphile selected from the group consisting of C 12-C 1 g fatty alcohols, C 12-C 1 g glycol monoesters, C 12-C 1 g g~yceryl mono- and diesters, propylene glycol stearate, sucrose distearate, and mixtures thereof; and a second non-phospholipid amphiphile selected from the group consisting of quaternary dimethyldiacyl amines, polyoxyethylene acyl alcohols, polyglycerols, sorbitan fatty acid esters, polyoxyethylene derivatives of sorbitan fatty acid esters, fatty acids and their salts, and mixtures thereof.
The present invention further relates to a method of forming the paucilamellar S lipid vesicles of the invention. A lipophilic phase containing at least one non-phospholipid amphiphile is first prepared and then blended with avocado oil unsaponifiables and any other oily material to be encapsulated into the vesicle to form a lipid phase. This lipid phase is then shear mixed with an aqueous phase containing an aqueous-based hydrating agent and any aqueous soluble material to be encapsulated into the vesicle to form lipid vesicles. "Shear mixing" is defined as the mixing of the lipid phase with the aqueous phase under turbulent or shear conditions which provide adequate mixing to hydrate the lipid and form lipid vesicles. "Shear mixing"
is achieved by liquid shear which is substantially equivalent to a relative flow rate for the combined phase of about 5-30m/s through a 1 mm orifice.
In order to achieve the proper blending necessary to form the paucilamellar vesicles of the present invention, all of the materials are normally in flowable state. This is easily achieved by elevating the temperature of the lipid phase in order to make it flowable followed by carrying out the shear mixing between the lipid phase and the aqueous phase at a temperature such that both phases are liquids.
In an aspect of the present invention there is provided a paucilamellar lipid vesicle having 2-10 bilayers surrounding an amorphous oil-filled central cavity, a portion of the oil filling of said oil-filled central cavity being supplied by avocado oil unsaponifiables, wherein each of said bilayers contains at least one non-phospholipid amphiphile selected from the group consisting of polyoxyethylene fatty esters, polyoxyethylene fatty acid ethers, diethanolamides, long chain acyl hexosamides, long chain acyl amino acid amides, long chain acyl amides, polyoxyethylene derivatives of fatty acid esters having 10-20 oxyethylene groups, POE (20) sorbitan mono- or trioletate, polyoxyethylene glyceryl monostearate with 1-10 oxyethylene groups, and glycerol monostearate as the -4a-primary lipid in said bilayers, and phytosterol supplied by said avocado oil unsaponifiables as a modulator in said bilayers.
In a further aspect of the present invention there is provided a method of forming a paucilamellar lipid vesicle having 2-10 lipid bilayers surrounding an oil-filled amorphous central cavity, said method comprising the steps of: A. preparing a lipophilic phase containing at least one non-phospholipid amphiphile selcted from the group consisting of polyoxyethylene fatty esters, polyoxyethylene fatty acid ethers, diethanolamides, long chain acyl hexosamides, long chain acyl amino acid amides, long chain acyl amides, polyoxyethylene derivatives of fatty acid esters having 10-oxyethylene groups, POE (20) sorbitan mono- or trioletate, polyoxyethylene glyceryl monostearate with 1-10 oxyethylene groups, and glycerol monostearate as the primary lipid to be incorporated into said bilayers; B. blending said lipophilic phase with avocado oil unsaponifiables and any other oily material to be encapsulated into said vesicle to form a lipid phase; C. preparing an aqueous phase of an aqueous-based hydrating agent and any aqueous soluble material to be encapsulated into said vesicle;
and D. shear mixing said lipid phase with said aqueous phase to form said lipid vesicle, without the formation of a separable lamellar phase, whereby said avocado oil unsaponifiables partition so that phytosterol from said avocado oil unsaponifiables is incorporated into the bilayers of said lipid vesicle and the remaining components of said avocado oil unsaponifiables are entrapped in the amorphous central cavity of said lipid vesicle.
In yet a further aspect of the present invention there is provided a paucilamellar lipid vesicle having 2-10 bilayers surrounding an amorphous oil-filled central cavity, wherein each of said bilayers contains at least one non-phospholipid amphiphile selected from the group consisting of polyoxyethylene fatty esters, polyoxyethylene fatty acid ethers, diethanolamides, long chain acyl hexosamides, long chain acyl amino acid amides, long chain acyl amides, POE (20) sorbitan mono- or trioletate, and glycerol monostearate as the primary lipid in said bilayers and phytosterol supplied by avocado oil -4b-unsaponifiables, said avocado oil unsaponifiables partitioning in manufacture of said paucilamellar lipid vesicles, so that a sufficient amount of the phytosterol from said avocado oil unsaponifiables goes into said bilayers so as to stabilize said bilayers and the remainder of said avocado oil unsaponifiables goes into said amorphous central cavity.
Preferably, said avocado oil unsaponifiables are provided in an amount of 20 to 65% by weight of the total weight of lipids in said paucilamellar lipid vesicle.
All of the materials used to form the vesicles of the invention can also be used in the methods of the invention. Other modifications of the methods and products will be apparent from the following description and claims.
Detailed Description of the Invention The lipid vesicles of the invention are paucilamellar lipid vesicles characterized by two to ten lipid bilayers or shells with small aqueous volumes separating each substantially spherical lipid shell. The innermost lipid bilayer surrounds a large, amorphous central cavity which is substantially filled with an oily solution.
The lipid bilayers of the vesicles contain a blend of at least one non-phospholipid amphiphile as the primary lipid of the bilayers and phytosterol supplied by avocado oil unsaponifiables which acts as a modulator. The avocado oil unsaponifiables provides two distinct benefits: first, it acts as a source of phytosterol for the bilayers, and second, it acts as a source of triglycerides which substantially fill the amorphous central cavity of the vesicles and serve as a moisturizer. This oily material also acts as a vesicle stabilizer.
The central cavity may further contain other oily materials.
The present invention relates to formulations for lipid vesicles and methods of their manufacture. More particularly, the present invention discloses paucimellar lipid vesicles designed of materials which have exceptional properties for cosmetic, edible, dermatological, and pharmaceutical use. The paucimellar vesicles have 2-10 lipid bilayers surrounding a large, amorphous central cavity which contains a water-immiscible oily material including triglycerides supplied by avocado oil unsaponifiables. The lipid bilayers of these vesicles contain at least one non-phospholipid amphiphile as the primary structural material of the lipid bilayers, along with phytosterol from avocado oil unsaponifiables which acts as a membrane or bilayer modulator.
Lipid vesicles are substantially spherical structures made of amphiphiles, e.g., surfactants or phospholipids. The lipids of these spherical vesicles are generally organized in the form of lipid bilayers, e.g., multiple onion-like shells of lipid bilayers which encompass an aqueous volume between the bilayers. Paucilamellar lipid vesicles have 2-10 peripheral bilayers which surround a large, unstructured central cavity.
Until recently, liposome technology has been concerned mostly with vesicles composed of phospholipids. This is primarily because phospholipids are the principal structural components of natural membranes and, accordingly, lipid vesicles have been used as a model system for studying natural membranes. However, there are a number of problems associated with using phospholipids as synthetic membranes.
Biological membranes are stabilized by membrane proteins and maintained by extensive enzymatic "support" systems that rapidly tum over, exchange or modify membrane lipids.
Neither membrane proteins nor the requisite enzymatic support systems can be practically incorporated into the wall structure of liposomes, making the structures inherently less stable than natural membranes. In addition, the biological environment contains several potent phospholipases that rapidly break down free phospholipids. These phospholipids will attack liposomes and degrade the membrane. For these reasons, phospholipid liposomes placed in an in vivo environment are rapidly degraded.
Moreover, phospholipid liposome technology has other problems. Phospholipids are labile and expensive to purify or synthesize. In addition, classic phospholipid liposomes are in the form of multilamellar as opposed to paucilamellar vesicles and have poor carrying capacities, especially for lipophilic materials, and have poor shelf lives unless lyophilized in the dark with antioxidants. While unilamellar vesicles (these only having one bilayer) add additional carrying capacity. they are much less stable. Finally, phospholipids degrade too rapidly in_ viv for most pharmaceutical or vaccine applications.
. For these reasons, there is increasing interest in liposomes made of commercially available nonphospholipid amphiphiles (see, e.g., U.S. Pat. No. 4,217,344, U.S
Pat. No.
4,917,951, and U.S. Pat. No. 4,911,928). These molecules have a hydrophilic "head" group attached to a hydrophobic "tail" and are derived from long chain fatty acids, long chain alcohols and their derivatives, long chain amines, and polyol sphingo- and glycerolipids.
Commercially available amphiphile surfactants include, for example, the BRIJ~
family of polyoxyethylene fatty ethers, the SPAN sorbitan fatty acid esters, the TWEEN'ethoxylated sorbitan fatty acid esters, glyceryl monostearate, glyceryl distearate, and glyceryl dilaurate, all available from ICI Americas, Inc. of Wilmington, De.
Paucilamellar vesicles comprised of such non-phospholipid amphiphiles provide a number of advantages over classical phospholipid multilamellar liposomes. For instance.
these vesicles have a high carrying capacity for water-soluble and water immiscible substances. Also, the amphiphiles used to make up the vesicle bilayers can often be used as emulsifiers or thickeners, providing the "feel" to certain cosmetics and/or dermatologicals.
Furthermore, many of these amphiphiles fall under the GRAS list of edible materials and therefore can be used in many food and pharmaceutical products.
It has previously been shown that when forming lipid vesicles containing at least one amphiphile as the primary lipid of the bilayers, the addition of a membrane modulator considerably improves the shape and size of lipid vesicles, as well as the consistency of the formulation after processing (See e.g., U.S. Patent No. 5,260,065). In the past, cholesterol has generally been used for this purpose. Sterols such as cholesterol also act to modify the thermotropic phase transition of the amphiphiles. However, cholesterol has the drawback of being an undesirable ingredient for use in most edible and pharmaceutical preparations.
Avocado oil unsaponifiables (a source of phytosterol) can be used instead of cholesterol as a bilayer modulator and provides many cosmetic, dermatological and pharmaceutical benefits. For example, it has a soft waxy consistency that confers a creamy texture to skin care products in addition to its moisturizing effects. Avocado oil unsaponifiables are also non-cytoxic, non-irritating and edible.
Accordingly, an object of the present invention is to provide a method of making paucimellar lipid vesicles using materials which are edible and/or have cosmetic, dermatological and pharmaceutical benefits.
'Trade-murk Another object of the invention is to provide paucilamellar lipid vesicles which contain a blend of at least one non-phospholipid amphiphile as the primary structural material of the bilayers and phytosterol supplied by avocado oil unsaponifiables as a modulator.
A further object of the invention is to provide a method of producing paucimellar lipid vesicles which readily encapsulate water immiscible oily materials and are manufactured from relatively inexpensive materials.
These and other objects and features of the invention will be apparent from the following description and the claims.
Summary of the Invention The present invention features paucilamellar lipid vesicles having 2-10 bilayers 1 ~ surrounding an amorphous central cavity which is substantially filled with an oily material.
The lipid bilayers contain at least one non-phospholipid amphiphile as the primary lipid and phvtosterol supplied by avocado oil unsaponifiables as a modulator. The lipid bilayers may further contain a negative charge producing agent, such as dicetyl phosphate, oleic acid, stearic acid, or mixtures thereof or a positive charge producing agent, such as quaternary ammonium compounds. The term "primary lipid", as used herein, means that this lipid is the major lipid, by weight, forming the structure of the lipid bilayers.
In a preferred embodiment, the primary non-phospholipid amphiphile is selected from the group consisting of polyoxyethylene fatty esters, polyoxyethylene fatty acid ethers, diethanolamides, long chain acyl hexosamides, long chain acyl amino acid amides, long chain acyl amides, polyoxyethylene derivatives of fatty acid esters having 10-20 oxyethylene groups, polyoxyethylene 20 sorbitan mono- or trioletate, polyoxyethylene glyceryl monostearate with 1-10 oxyethylene groups, and glycerol monostearate. In another preferred embodiment, the bilayers further contain a phospholipid, a glycolipid, and mixtures thereof.
In yet another preferred embodiment, the primary non-phospholipid amphiphile is selected from the group consisting of betaines and anionic sarcosinamides.
In still another preferred embodiment, the bilayers contain both a primary non-phospholipid amphiphile selected from the group consisting of C 12-C 1 g fatty alcohols, C 12-C 1 g glycol monoesters, C 12-C 1 g g~yceryl mono- and diesters, propylene glycol stearate, sucrose distearate, and mixtures thereof; and a second non-phospholipid amphiphile selected from the group consisting of quaternary dimethyldiacyl amines, polyoxyethylene acyl alcohols, polyglycerols, sorbitan fatty acid esters, polyoxyethylene derivatives of sorbitan fatty acid esters, fatty acids and their salts, and mixtures thereof.
The present invention further relates to a method of forming the paucilamellar S lipid vesicles of the invention. A lipophilic phase containing at least one non-phospholipid amphiphile is first prepared and then blended with avocado oil unsaponifiables and any other oily material to be encapsulated into the vesicle to form a lipid phase. This lipid phase is then shear mixed with an aqueous phase containing an aqueous-based hydrating agent and any aqueous soluble material to be encapsulated into the vesicle to form lipid vesicles. "Shear mixing" is defined as the mixing of the lipid phase with the aqueous phase under turbulent or shear conditions which provide adequate mixing to hydrate the lipid and form lipid vesicles. "Shear mixing"
is achieved by liquid shear which is substantially equivalent to a relative flow rate for the combined phase of about 5-30m/s through a 1 mm orifice.
In order to achieve the proper blending necessary to form the paucilamellar vesicles of the present invention, all of the materials are normally in flowable state. This is easily achieved by elevating the temperature of the lipid phase in order to make it flowable followed by carrying out the shear mixing between the lipid phase and the aqueous phase at a temperature such that both phases are liquids.
In an aspect of the present invention there is provided a paucilamellar lipid vesicle having 2-10 bilayers surrounding an amorphous oil-filled central cavity, a portion of the oil filling of said oil-filled central cavity being supplied by avocado oil unsaponifiables, wherein each of said bilayers contains at least one non-phospholipid amphiphile selected from the group consisting of polyoxyethylene fatty esters, polyoxyethylene fatty acid ethers, diethanolamides, long chain acyl hexosamides, long chain acyl amino acid amides, long chain acyl amides, polyoxyethylene derivatives of fatty acid esters having 10-20 oxyethylene groups, POE (20) sorbitan mono- or trioletate, polyoxyethylene glyceryl monostearate with 1-10 oxyethylene groups, and glycerol monostearate as the -4a-primary lipid in said bilayers, and phytosterol supplied by said avocado oil unsaponifiables as a modulator in said bilayers.
In a further aspect of the present invention there is provided a method of forming a paucilamellar lipid vesicle having 2-10 lipid bilayers surrounding an oil-filled amorphous central cavity, said method comprising the steps of: A. preparing a lipophilic phase containing at least one non-phospholipid amphiphile selcted from the group consisting of polyoxyethylene fatty esters, polyoxyethylene fatty acid ethers, diethanolamides, long chain acyl hexosamides, long chain acyl amino acid amides, long chain acyl amides, polyoxyethylene derivatives of fatty acid esters having 10-oxyethylene groups, POE (20) sorbitan mono- or trioletate, polyoxyethylene glyceryl monostearate with 1-10 oxyethylene groups, and glycerol monostearate as the primary lipid to be incorporated into said bilayers; B. blending said lipophilic phase with avocado oil unsaponifiables and any other oily material to be encapsulated into said vesicle to form a lipid phase; C. preparing an aqueous phase of an aqueous-based hydrating agent and any aqueous soluble material to be encapsulated into said vesicle;
and D. shear mixing said lipid phase with said aqueous phase to form said lipid vesicle, without the formation of a separable lamellar phase, whereby said avocado oil unsaponifiables partition so that phytosterol from said avocado oil unsaponifiables is incorporated into the bilayers of said lipid vesicle and the remaining components of said avocado oil unsaponifiables are entrapped in the amorphous central cavity of said lipid vesicle.
In yet a further aspect of the present invention there is provided a paucilamellar lipid vesicle having 2-10 bilayers surrounding an amorphous oil-filled central cavity, wherein each of said bilayers contains at least one non-phospholipid amphiphile selected from the group consisting of polyoxyethylene fatty esters, polyoxyethylene fatty acid ethers, diethanolamides, long chain acyl hexosamides, long chain acyl amino acid amides, long chain acyl amides, POE (20) sorbitan mono- or trioletate, and glycerol monostearate as the primary lipid in said bilayers and phytosterol supplied by avocado oil -4b-unsaponifiables, said avocado oil unsaponifiables partitioning in manufacture of said paucilamellar lipid vesicles, so that a sufficient amount of the phytosterol from said avocado oil unsaponifiables goes into said bilayers so as to stabilize said bilayers and the remainder of said avocado oil unsaponifiables goes into said amorphous central cavity.
Preferably, said avocado oil unsaponifiables are provided in an amount of 20 to 65% by weight of the total weight of lipids in said paucilamellar lipid vesicle.
All of the materials used to form the vesicles of the invention can also be used in the methods of the invention. Other modifications of the methods and products will be apparent from the following description and claims.
Detailed Description of the Invention The lipid vesicles of the invention are paucilamellar lipid vesicles characterized by two to ten lipid bilayers or shells with small aqueous volumes separating each substantially spherical lipid shell. The innermost lipid bilayer surrounds a large, amorphous central cavity which is substantially filled with an oily solution.
The lipid bilayers of the vesicles contain a blend of at least one non-phospholipid amphiphile as the primary lipid of the bilayers and phytosterol supplied by avocado oil unsaponifiables which acts as a modulator. The avocado oil unsaponifiables provides two distinct benefits: first, it acts as a source of phytosterol for the bilayers, and second, it acts as a source of triglycerides which substantially fill the amorphous central cavity of the vesicles and serve as a moisturizer. This oily material also acts as a vesicle stabilizer.
The central cavity may further contain other oily materials.
The following Examples will clearly illustrate the efficacy of the invention.
Fxa~ male 1 In this Example, oil-filled lipid vesicles were formed using avocado oil unsaponifiables obtained from Croda Inc., Parsippany N.J., with and without additional cholesterol, as a component of the lipid bilayers. Propylene glycol stearate was used as the primary amphiphile of the lipid bilayers. Polysorbate 60~(polyoxyethylene 20 sorbitan monostearate) and/or stearyl alcohol were added to Samples A, C and D as secondary amphiphiles or spacers.
Composition Sample (grams) A B C D
Propylene Glycol Stearate 1.75 2.5 2.5 2.5 Stearyl Alcohol 0.35 0.5 0.5 Polysorbate 60 0.25 0.35 Cholesterol 0.5 Avocado Oil Unsaponifiables*4.0 2.5 2.5 2.5 Water 28.6 30 30 29 * 1 gram Avocado oil unsaponifiables contains about 0.3 grams phyrtosterol In this Example, oil-filled vesicles were formed using the hot loading technique described in United States Patent No. 4,911,928. Briefly, the vesicles were hot loaded by heating the lipid phase consisting of avocado oil unsaponifiables and the appropriate ~0 amphiphile(s) to 85°C, and then hydrating the lipid phase by the aqueous phase at 65°C.
Hydration to form lipid vesicles was achieved by shear mixing the lipid and aqueous phases using two 60 cc syringes, connected by a stopcock. The lipid and aqueous phases were blended from one syringe to the other, forming vesicles in two minutes or less.
. However, in this and the following Examples, any method of achieving the proper shear could be used. Preferably, a flow device such as the NovaMixTM vesicle former is used. The basic details of the NovaMixT"' system are described in United States Patent No. 4.895.452.
"Trade-mark After processing to form lipid vesicles, sample B had a cottage cheese-like consistency, while sample C had only partially hydrated lipid and clear water.
These samples were not examined further.
S After processing to form lipid vesicles, samples A and D had a smooth, lotion-like consistency. Microscopic examination of these samples showed nice, small, spherical vesicles with maltese crosses, indicating multiples concentric lipid bilayers.
The mean diameters of these vesicles measured 1460 nm and 913 nm respectively. When centrifuged at 3500 rpm for 30 minutes, samples A and D both showed some separation, probably due to an excess of water. Sample A, which contained 4.0 grams of avocado oil unsaponifiables with no additional cholesterol, contained a slightly better, more homogenous population of vesicles than did sample D, which contained cholesterol and only 2.5 grams of avocado oil unsaponifiables.
This Example shows that avocado oil unsaponifiables, preferably ranging from 20-6~
percent by weight of the lipid, can be used along with or, more preferably, instead of cholesterol in the formation of oil-filled lipid vesicles. Avocado oil unsaponifiables provides the advantage of acting both as a source of phytosterol in the lipid bilayers, as well as a source of triglycerides which partially fill the central cavity of the vesicles, serving as a moisturizing agent Example 2 In this Example, samples A-C were designed to form oil-filled paucilamellar vesicles using as the primary structural components of the lipid bilayers an amphiphile selected from the group consisting of glyceryl dilaurate, glyceryl monostearate, or glyceryl distearate, and phytosterol from avocado oil unsaponifiables (obtained from Croda Inc., Parsippany, N.J.).
Samples B and C also contained a secondary amphiphile which acted as a spacer molecule, consisting of either Polysorbate 60 (polyoxyethylene 20 sorbitan monostearate) or Brij 76 (polyoxyethylene 10 stearyl alcohol).
"Trade Mark TAB
Vesicle Components (grams) A B C
Brij 76'' 1.6 Glyceryl Dilaurate 3.0 Glyceryl Monostearate 2.55 Glyceryl Distearate 2.0 Polysorbate 60~ 0.67 Avocado Oil Unsaponifiables* 4.0 4.0 3.0 Water 30.0 35.0 40.0 * 1 gram of Avocado Oil Unsaponifiables contains approximately 0.3 grams of phytosterol.
Oil-filled vesicles were formed using the hot loading technique described in Example l, except that the aqueous phase was heated to 70°C instead of 65°C.
After processing to form lipid vesicles, all three Samples had a nice fluid consistency.
Upon microscopic examination, Sample A had two populations of vesicles consisting of small, birefringent vesicles with maltese cross patterns (indicating multiple concentric bilayers) and larger, aggregated vesicles. Sample B contained small, hetro-sized, birefringent vesicles with maltese cross patterns. Sample C contained the best vesicles of the three samples and was made up of homogenous, small, birefringent vesicles with maltese cross patterns. The mean particle diameter of the vesicles of Samples A-C, measured by Coulter Counter (Coulter Counter Electronics Corp., Miami, FL), was approximately 1190 nm, 1420 nm and 380 nm, respectively.
After centrifugation at 3500 rpm for 15 minutes, Sample A (containing no secondary amphiphile) separated into two phases consisting of approximately 25 ml of turbid solution at the bottom of the Sample and approximately 10 ml of creamy solution at the top. Samples B
and D showed no separation, probably due to the addition of a secondary amphiphile.
These results show that paucilamellar lipid vesicles can be formed using avocado oil unsaponifiables instead of cholesterol or other membrane modulators, along with an amphiphile, to form the lipid bilayers of paucilamellar vesicles. The addition of a secondary ,, amphiphile, preferably Brij 76 (~ Sample C), improves the size and shape of the vesicles.
Avocado oil unsaponifiables provides the advantage of acting both as a source of phyosterol in the lipid bilayers, as well as a source of triglycerides which are encapsulated in the central cavity and serve as a moisturizing agent.
'Trade-mark -g-Example s In this Example, oil-filled paucilamellar lipid vesicles were formed using avocado oil unsaponifiables (obtained from Croda Inc., Parsippany, N.J.) along with a primary .
amphiphile consisting of either polyoxyethylene 2 cetyl ether (Brij 52) or polyoxyethylene 9 glyceryl monostearate (POE 9 GMS). For Samples B and C, phosphate buffer saline (PBS) .
was used instead of water as the hydrating agent.
TABLF~
IO
Vesicle Components Sample (grams) A B C D
j, 1.8 1.8 Brij 52 POE 9 GMS 2.7 2.7 Avocado Oil Unsaponifiables*1.2 1.2 1.7 1.7 Water 16.0 13.0 pBS 16.0 13.0 1 S * 1 gram of Avocado Oil Unsaponifiables contains approximately 0.3 gm of phytosterol.
Oil-filled vesicles were formed using the hot loading technique described in Example 1, except that the lipid phase was heated to 70°C and hydrated by the aqueous phase at 65°C.
20 Hydration to form lipid vesicles was achieved using 20cc syringes in place of the 60cc syringes used in Example 1.
After processing for lipid vesicles, Samples A and B were thick and viscous, while Samples C and D were fluid.
Microscopic examination of all four samples showed very nice, small, spherical vesicles. The mean particle diameter of the vesicles of Samples A-D were 1040nm, 809 nm, 444 nm and 430 nm, respectively.
This Example shows that the combination of POE 9 GMS and avocado oil unsaponifiables forms better vesicles, both in shape and in consistency of formulation, than X
does the combination of Brij52"and avocado unsaponifiables. This Example also shows that PBS can be used instead of water as a hydrating agent.
'Trade Mark F~,ample 4 In this Example, a variety of different primary amphiphiles were used in combination with avocado oil unsaponifiables (obtained from Croda Inc., Parsippany, N.J.) to form the lipid bilayers For each of oil-filled Sample, paucilamellar vesicles vesicles. were made with - phytosterol, 15% by weight supplied of bilayer by avocado oil unsaponifiables, being mat erial and 3.8% by weight of the total vesicle.
Avacado Oil Unsaponifia Wate bles* r A POE10 Cetyl Alcohol (Brij 1.7 gm 1.0 gm 16 ml 56)"
B POE2 Stearyl Alcohol (Brij 1.7 gm 1.0 gm 16 ml 72) ,~
C POE10 Stearyl Alcohol (Brij 1.7 gm 1.0 gm 16 ml 76) ~~
D POE10 Oleyl Alcohol (Brij 1.7 gm 1.0 gm 16 ml 97)~
E POE4 Lauryl Alcohol (Brij 1.7 gm 1.0 gm 16 ml 30~' F POE2 Oleyl Alcohol (Brij 92) 1.7 gm 1.0 gm 16 ml ~
G Y 1.7 gm 1.0 gm 16 ml POE20 Sorbitan Monostearate (Tween 6~~
H POE20 Sorbitan Monooleate 1.7 gm 1.0 gm 16 ml (Tween 80) I POE8 Stearate (Myrj 45) 1.7 gm 1.0 gm 16 ml J DEA Lactic Amide (Mona 150 1.7 gm 1.0 gm 16 ml LWA) K DEA Lauric Amide (Mona 150 1.7 gm 1.0 gm 16 ml LWA) L DEA Linoleic Amide (Mona 15-70w)1.7 mg 1.0 gm 16 ml * 1 gram of Avocado Oil Unsaponifiables contains approximately 0.3 gm of phytosterol *POE is polyoxyethylene *DEA is diethanolamide Oil-filled vesicles were formed using the hot loading method described in Example 1, except that the lipid phase was heated to 70°C and hydrated by the aqueous phase at 60°C.
Hydration to form lipid vesicles was achieved using 20cc syringes in place of the 60cc syringes used in Example 1. After processing to form lipid vesicles, the following results were observed:
Sample A (Brij 56'and avocado oil unsaponifiables) had a fluid consistency.
Upon microscopic examination, many heterogenous, but small vesicles were visible.
After centrifugation at 3500 rpm for 15 minutes, no separation was observed, but a small amount of creaming formed on top of the Sample. Mean particle size of the vesicles, measured by Coulter Counter, was 254 nm.
"Trade Mark Sample B (Brij 72~and avocado oil unsaponifiables) had a lotion-like consistency.
Upon microscopic examination, many heterogenous vesicles were visible. After centrifugation at 3500 rpm for 15 minutes, no separation was observed. Mean particle size of the vesicles, measured by Coulter Counter, was 765 nm.
Sample C (Brij 76~~and avocado oil unsaponifiables) had a fluid consistency.
Upon microscopic examination, very nice small vesicles were visible. After centrifugation at 3500 rpm for 15 minutes, 2 ml of hazy solution separated as infernatant. Mean particle size of the vesicles, measured by Coulter Counter, was 281 run.
Sample D (Brij 9'7~and avocado oil unsaponifiables) had a very fluid consistency.
Upon microscopic examination, both very nice small vesicles and some large vesicles were visible. After centrifugation at 3500 rpm for 15 minutes, no separation was observed, but a small amount of creaming formed on top of the Sample. Mean particle size of the vesicles, measured by Coulter Counter, was 151 nm.
Sample E (Brij 30jand avocado oil unsaponifiables) had a very fluid consistency.
Upon microscopic examination, both very nice small vesicles and some large vesicles were visible. After centrifugation at 3500 rpm for 15 minutes, no separation was observed, but a small amount of creaming formed on top of the Sample. Mean particle size of the vesicles, measured by Coulter Counter, was 348 nm.
Sample F (Brij 92 and avocado oil unsaponifiables) had a fluid consistency.
Upon microscopic examination, nice spherical vesicles were visible. After centrifugation at 3500 rpm for 15 minutes, 1 ml of turbid aqueous solution separated as infernatant.
Mean particle size of the vesicles, measured by Coulter Counter, was 381 nm.
Sample G (Tween 60 and avocado oil unsaponifiables) had a very fluid consistency.
Upon microscopic examination, extremely small homogenous vesicles were visible. After centrifugation at 3500 rpm for 15 minutes, no separation was observed, but a small amount of creaming formed on top of the Sample. Mean particle size of the vesicles, measured by Coulter Counter, was 151 nm.
Sample H (Tween 80 and avocado oil unsaponifiables) had the same consistency and size vesicles as Sample G. After centrifugation at 3500 rpm for 15 minutes, no separation was observed. Mean particle size of the vesicles, measured by Coulter Counter, was 164 nm.
Sample I (Myrj 45 and avocado oil unsaponifiables) had a fluid consistency.
Upon microscopic examination, very nice looking small vesicles were visible. After centrifugation 'Trade Mark at 3500 rpm for 1 ~ minutes, no separation was observed, but the Sample took on a lotion-like consistency. Mean particle size of the vesicles, measured by Coulter Counter, was 310 nm.
Sample J (Mona 150 LWA and avocado oil unsaponifiables) had a creamy ~ consistency. Upon microscopic examination, the vesicles appeared similar to those of Sample I (small and nice looking). After centrifugation at 3500 rpm for 15 minutes, no separation was observed. Mean particle size of the vesicles, measured by Coulter Counter, was 252 nm.
Sample K (Mona 150 LWA and avocado oil unsaponifiables) had a fairly thick, creamy consistency. Upon microscopic examination, nicely shaped heterogenous vesicles were visible. After centrifugation at 3500 rpm for 15 minutes, no separation was observed.
Mean particle size of the vesicles, measured by Coulter Counter, was 644 nm.
1 ~ Sample L (Mona 15-70w and avocado oil unsaponifiables) had the same consistency as Sample K. Upon microscopic examination, the vesicles also appeared similar to those of Sample K, except that they were smaller. After centrifugation at 3500 rpm for 1 S minutes, no separation was observed. Mean particle size of the vesicles, measured by Coulter Counter, was 218 nm.
This Example shows that avocado oil unsaponifiables can be used in combination with a variety of primary amphiphiles, in particular the Tween family of ethoxylated sorbitan J.
fatty acid esters, the Brij family of polyoxyethylene fatty ethers, the Myrj family of polyoxyethylene derivatives of stearic acid, and the Mona family of diethanolamides to form 2~ good lipid vesicles. None of the samples showed birefringence, probably due to the small particle size of the vesicles.
Exam lie 5 In this Example lipid vesicles for use in hair conditioners were formed. The primary amphiphile making up the lipid bilayers consisted of glyceryl distearate in Sample A and polyoxyethylene (8) stearate in Sample B. Stearyl alcohol was added as a secondary amphiphile. The lipid bilayers also contained phytosterol from avocado oil unsaponifiables (supplied by Croda Inc., Parsippany, N.J.). Distearyldimonium chloride was used as a positive charge producing agent.
3~
In the aqueous phase, sodium laurel sulfate (30%) was used as a secondary emulsifier, along with methyldibromo glutaronitrile phenoxyethenol polyquaterniurn 7 as a preservative. Cetyl trimethyl ammonium chloride was used as a positive charge producing agent.
*Trade Mark (% by ght) wei A B Lipid Phase 1.5 0.5 Stearyl Alcohol 2.0 Glyceryl Distearate 1.7 Polyoxyethylene (8) Stearate 3.33 1.0 Avocado Oil Unsaponifiables*
2.5 2.5 Distearyldimonium Chloride Aqueous Phase 0.5 0.5 Sodium Laurel Sulfate 30%
0.1 0.1 Methyldibromo Glutaronitrile Phenoxyethenol Polyquaternium 7 0.1 2.0 Cetyl Trimethyl Ammonium Chloride 88.0 91.7 Deionized Water * 1 gram of Avocado Oil Unsaponifiables contains approximately 0.3 gm of phytosterol The lipid vesicles were hot loaded according to the method described in Example 1.
Sample A was processed using a hydration ratio of 1 part lipid at 80°C
to 9.5 parts aqueous at 70°C. Sample B was processed using a hydration ratio of 1 part lipid at 90°C to 16.5 parts aqueous at 70°C.
After processing to form lipid vesicles, both Samples A and B had a creamy consistency, appropriate for use as a hair conditioner. Upon microscopic examination, the vesicles of both Samples were very good and homogenous.
This Example shows that avocado oil unsaponifiables, which acts both as a structural component of lipid vesicles by supplying phytosterol to the lipid walls, as well as a moisturizing agent by supplying triglycerides to the central cavity can be used along with amphiphiles which also have cosmetic (e.g., moisturizing) properties, such as glyceryl distearate and polyoxyethylene 8 stearate, to form good lipid vesicles suitable for use in cosmetics. Other useful materials (i.e., emulsifiers and preservatives) can also be added to the aqueous portion of the lipid vesicles, such as sodium laurel sulfate (30%) and methyldibromo glutaronitrile phenoxyethenol polyquaternium 7.
xam~le 6 In this Example, lipid vesicles were formed for use in a skin rejuvenating cream.
Polyoxyethylene 8 stearate was used as the primary amphiphile and stearyl alcohol, stearyl alcohol-Ceteareth 20 and cetearyl alcohol-Ceteareth 20 were used as the secondary' amphiphiles making up the lipid bilayers. Avocado oil unsaponifiables was also added to provide phytosterol to the bilayers and triglycerides to the central cavity. A
variety of other moisturizing agents were also added to the lipid phase, such as shark liver oil, petrolatum lanolin-lanolin alcohol, benzoic acid alkyl esters and cetyl acetate-acetylated lanolin alcohol, all of which were encapsulated in the central core of the lipid vesicles.
Tocopherol concentrate (vitamin E) and BHA (butylated hydroxy anisol) were added to the lipid phase as antioxidants.
The aqueous portion of the lipid vesicles contained glycerin (99%) and butylene glycol as humectants, sodium DL2 pyrrolidone 5 carboxylate, aloe vera concentrate, SRF
(skin respiratory factor) and collagen as moisturizers, di sodium EDTA as a chelating agent, and methyldibromo glutaronitrile phenoxyethenol polyquaternium 7 as an antibacterial agent.
by Weight LIPID PHASE
0.5 Shark Liver Oil 0.1 Petrolatum-Lanolin-Lanolin Alcohol 0.5 Benzoic Acid-C12 - 15 Alkyl Esters 0.1 TOCOPHEROL Concentrate (Vitamin E) 1.5 Copolyol 3.0 Stearyl Alcohol - Ceteareth - 20 0.~ Stearyl Alcohol 1.0 Cetearyl Alcohol - Ceteareth -1.7 Polyoxyethylene (8) Stearate 1.0 Avocado Oil Unsaponifiables 0.04 Fragrance 0.1 BHA
1.0 Cetyl Acetate - Acetylated Lanolin Alcohol AQUEOUS PHASE
4.0 Glycerin 99%
6.0 Butylene Glycol 1.0 Sodium DL2 Pyrrolidone S - Carboxylate 0.2 Aloe Vera Concentrate 0.1 Di Sodium EDTA
0.1 Collagen 0.2 Methyldibromo Glutaronitrile Phenoxyethenol Polyquaternium 7 0.05 SRF Powder 77.31 Deionized Water The lipid vesicles were hot loaded according to the method described in Example I .
A hydration ratio of 1 part lipid at 80°C to 16.5 parts aqueous at 70°C was used. After processing to form lipid vesicles, the sample had a creamy consistency, appropriate for use as a skin rejuvenating cream. Upon microscopic examination, the vesicles were very good S looking and homogenous.
This Example shows that a variety of amphiphiles which have cosmetic properties (i.e., moisturizers) can be used in combination with avocado oil unsaponifiables to form the lipid bilayers and to fill the central cavity of vesicles for use in skin creams. Avocado oil unsaponifiables provides the advantage of acting both as a good structural component of vesicles by providing phytosterol to the lipid bilayers, as well as a moisturizing agent by providing triglycerides to the central cavity.
Examnlg 7 In this Example, lactic acid carrying lipid vesicles were formed for use in .dermatologicals. The lipid bilayers of the vesicles were made up of glycerol distearate as the primary amphiphile, polyoxyethylene 10 stearyl ether, stearyl alcohol-Ceteareth 20, cetearyl alcohol-Ceteareth 20 and stearyl alcohol as secondary amphiphiles, and phytosterol supplied by avocado oil unsaponifiables. Other materials included in the lipid phase to be encapsulated in the central core of the vesicles were lactic acid (88%) (a dead skin cell remover), and cetyl acetate-acetylated lanolin alcohol, alkyl lactate and octyl hydroxystearate (skin moisturizers).
The aqueous phase included methyl paraben as a preservative, Bronopol (methyldibromo glutaronitrile phenoxyethenol polyquaternium 7) and propyl paraben as antibacterials, glycerin (96%) as a humectant, and Polysorbate 80~(polyoxyethylene 20 sorbitan monooleate) as a secondary emulsifier.
by Weight LIPID PHASE
5.7 Lactic Acid 88%
1.4 Polyoxyethylene 10 Stearyl Ether 3.3 Avocado Oil Unsaponifiables 6.3 Octyl Hydroxystearate 2.8 Glycerol Distearate 3.0 Stearyl Alcohol - Ceteareth 20 1.0 Cetearyl Alcohol - Ceteareth 20 1.0 Stearyl Alcohol 1.0 Cetyl Acetate and Acetylated Lanolin Alcohol 1.5 C 12-15 Alkyl Lactate "Trade Mark AQUEOUS PHASE
0.2 Methyl Paraben 4.0 Glycerin 96%
S 1.24 Sodium Hydroxide 0.03 Propyl Paraben 0.10 Sodium Chloride f Y_ 0.75 Polysorbate 80 0.05 Bronopol 4.0 Silicone Emulsion 0.2 Fragrance 62.93 Deionized Water The lipid vesicles were hot loaded according to the method described in Example 1.
A hydration ratio of 1 part lipid at 70°C to 16.5 parts aqueous at 60°C was used. After processing, the sample had a creamy consistency, appropriate for use in dermatological preparations. Upon microscopic examination, the vesicles were very good looking and homogenous.
This Example shows that avocado oil unsaponifiables can be used with amphiphiles and other materials having dermatological properties to form lipid vesicles for use in dermatologicals. Avocado oil unsaponifiables provides the advantage of acting both as a source of phytosterol for the lipid bilayers, as well as a source of triglycerides (moisturizing agent) to be encapsulated in the central cavity of the vesicles.
The foregoing Examples are merely illustrative and those skilled in the art may be able to determine other materials and methods which accomplish the same results. Such other materials and methods are included within the following claims.
*Trade Mark
Fxa~ male 1 In this Example, oil-filled lipid vesicles were formed using avocado oil unsaponifiables obtained from Croda Inc., Parsippany N.J., with and without additional cholesterol, as a component of the lipid bilayers. Propylene glycol stearate was used as the primary amphiphile of the lipid bilayers. Polysorbate 60~(polyoxyethylene 20 sorbitan monostearate) and/or stearyl alcohol were added to Samples A, C and D as secondary amphiphiles or spacers.
Composition Sample (grams) A B C D
Propylene Glycol Stearate 1.75 2.5 2.5 2.5 Stearyl Alcohol 0.35 0.5 0.5 Polysorbate 60 0.25 0.35 Cholesterol 0.5 Avocado Oil Unsaponifiables*4.0 2.5 2.5 2.5 Water 28.6 30 30 29 * 1 gram Avocado oil unsaponifiables contains about 0.3 grams phyrtosterol In this Example, oil-filled vesicles were formed using the hot loading technique described in United States Patent No. 4,911,928. Briefly, the vesicles were hot loaded by heating the lipid phase consisting of avocado oil unsaponifiables and the appropriate ~0 amphiphile(s) to 85°C, and then hydrating the lipid phase by the aqueous phase at 65°C.
Hydration to form lipid vesicles was achieved by shear mixing the lipid and aqueous phases using two 60 cc syringes, connected by a stopcock. The lipid and aqueous phases were blended from one syringe to the other, forming vesicles in two minutes or less.
. However, in this and the following Examples, any method of achieving the proper shear could be used. Preferably, a flow device such as the NovaMixTM vesicle former is used. The basic details of the NovaMixT"' system are described in United States Patent No. 4.895.452.
"Trade-mark After processing to form lipid vesicles, sample B had a cottage cheese-like consistency, while sample C had only partially hydrated lipid and clear water.
These samples were not examined further.
S After processing to form lipid vesicles, samples A and D had a smooth, lotion-like consistency. Microscopic examination of these samples showed nice, small, spherical vesicles with maltese crosses, indicating multiples concentric lipid bilayers.
The mean diameters of these vesicles measured 1460 nm and 913 nm respectively. When centrifuged at 3500 rpm for 30 minutes, samples A and D both showed some separation, probably due to an excess of water. Sample A, which contained 4.0 grams of avocado oil unsaponifiables with no additional cholesterol, contained a slightly better, more homogenous population of vesicles than did sample D, which contained cholesterol and only 2.5 grams of avocado oil unsaponifiables.
This Example shows that avocado oil unsaponifiables, preferably ranging from 20-6~
percent by weight of the lipid, can be used along with or, more preferably, instead of cholesterol in the formation of oil-filled lipid vesicles. Avocado oil unsaponifiables provides the advantage of acting both as a source of phytosterol in the lipid bilayers, as well as a source of triglycerides which partially fill the central cavity of the vesicles, serving as a moisturizing agent Example 2 In this Example, samples A-C were designed to form oil-filled paucilamellar vesicles using as the primary structural components of the lipid bilayers an amphiphile selected from the group consisting of glyceryl dilaurate, glyceryl monostearate, or glyceryl distearate, and phytosterol from avocado oil unsaponifiables (obtained from Croda Inc., Parsippany, N.J.).
Samples B and C also contained a secondary amphiphile which acted as a spacer molecule, consisting of either Polysorbate 60 (polyoxyethylene 20 sorbitan monostearate) or Brij 76 (polyoxyethylene 10 stearyl alcohol).
"Trade Mark TAB
Vesicle Components (grams) A B C
Brij 76'' 1.6 Glyceryl Dilaurate 3.0 Glyceryl Monostearate 2.55 Glyceryl Distearate 2.0 Polysorbate 60~ 0.67 Avocado Oil Unsaponifiables* 4.0 4.0 3.0 Water 30.0 35.0 40.0 * 1 gram of Avocado Oil Unsaponifiables contains approximately 0.3 grams of phytosterol.
Oil-filled vesicles were formed using the hot loading technique described in Example l, except that the aqueous phase was heated to 70°C instead of 65°C.
After processing to form lipid vesicles, all three Samples had a nice fluid consistency.
Upon microscopic examination, Sample A had two populations of vesicles consisting of small, birefringent vesicles with maltese cross patterns (indicating multiple concentric bilayers) and larger, aggregated vesicles. Sample B contained small, hetro-sized, birefringent vesicles with maltese cross patterns. Sample C contained the best vesicles of the three samples and was made up of homogenous, small, birefringent vesicles with maltese cross patterns. The mean particle diameter of the vesicles of Samples A-C, measured by Coulter Counter (Coulter Counter Electronics Corp., Miami, FL), was approximately 1190 nm, 1420 nm and 380 nm, respectively.
After centrifugation at 3500 rpm for 15 minutes, Sample A (containing no secondary amphiphile) separated into two phases consisting of approximately 25 ml of turbid solution at the bottom of the Sample and approximately 10 ml of creamy solution at the top. Samples B
and D showed no separation, probably due to the addition of a secondary amphiphile.
These results show that paucilamellar lipid vesicles can be formed using avocado oil unsaponifiables instead of cholesterol or other membrane modulators, along with an amphiphile, to form the lipid bilayers of paucilamellar vesicles. The addition of a secondary ,, amphiphile, preferably Brij 76 (~ Sample C), improves the size and shape of the vesicles.
Avocado oil unsaponifiables provides the advantage of acting both as a source of phyosterol in the lipid bilayers, as well as a source of triglycerides which are encapsulated in the central cavity and serve as a moisturizing agent.
'Trade-mark -g-Example s In this Example, oil-filled paucilamellar lipid vesicles were formed using avocado oil unsaponifiables (obtained from Croda Inc., Parsippany, N.J.) along with a primary .
amphiphile consisting of either polyoxyethylene 2 cetyl ether (Brij 52) or polyoxyethylene 9 glyceryl monostearate (POE 9 GMS). For Samples B and C, phosphate buffer saline (PBS) .
was used instead of water as the hydrating agent.
TABLF~
IO
Vesicle Components Sample (grams) A B C D
j, 1.8 1.8 Brij 52 POE 9 GMS 2.7 2.7 Avocado Oil Unsaponifiables*1.2 1.2 1.7 1.7 Water 16.0 13.0 pBS 16.0 13.0 1 S * 1 gram of Avocado Oil Unsaponifiables contains approximately 0.3 gm of phytosterol.
Oil-filled vesicles were formed using the hot loading technique described in Example 1, except that the lipid phase was heated to 70°C and hydrated by the aqueous phase at 65°C.
20 Hydration to form lipid vesicles was achieved using 20cc syringes in place of the 60cc syringes used in Example 1.
After processing for lipid vesicles, Samples A and B were thick and viscous, while Samples C and D were fluid.
Microscopic examination of all four samples showed very nice, small, spherical vesicles. The mean particle diameter of the vesicles of Samples A-D were 1040nm, 809 nm, 444 nm and 430 nm, respectively.
This Example shows that the combination of POE 9 GMS and avocado oil unsaponifiables forms better vesicles, both in shape and in consistency of formulation, than X
does the combination of Brij52"and avocado unsaponifiables. This Example also shows that PBS can be used instead of water as a hydrating agent.
'Trade Mark F~,ample 4 In this Example, a variety of different primary amphiphiles were used in combination with avocado oil unsaponifiables (obtained from Croda Inc., Parsippany, N.J.) to form the lipid bilayers For each of oil-filled Sample, paucilamellar vesicles vesicles. were made with - phytosterol, 15% by weight supplied of bilayer by avocado oil unsaponifiables, being mat erial and 3.8% by weight of the total vesicle.
Avacado Oil Unsaponifia Wate bles* r A POE10 Cetyl Alcohol (Brij 1.7 gm 1.0 gm 16 ml 56)"
B POE2 Stearyl Alcohol (Brij 1.7 gm 1.0 gm 16 ml 72) ,~
C POE10 Stearyl Alcohol (Brij 1.7 gm 1.0 gm 16 ml 76) ~~
D POE10 Oleyl Alcohol (Brij 1.7 gm 1.0 gm 16 ml 97)~
E POE4 Lauryl Alcohol (Brij 1.7 gm 1.0 gm 16 ml 30~' F POE2 Oleyl Alcohol (Brij 92) 1.7 gm 1.0 gm 16 ml ~
G Y 1.7 gm 1.0 gm 16 ml POE20 Sorbitan Monostearate (Tween 6~~
H POE20 Sorbitan Monooleate 1.7 gm 1.0 gm 16 ml (Tween 80) I POE8 Stearate (Myrj 45) 1.7 gm 1.0 gm 16 ml J DEA Lactic Amide (Mona 150 1.7 gm 1.0 gm 16 ml LWA) K DEA Lauric Amide (Mona 150 1.7 gm 1.0 gm 16 ml LWA) L DEA Linoleic Amide (Mona 15-70w)1.7 mg 1.0 gm 16 ml * 1 gram of Avocado Oil Unsaponifiables contains approximately 0.3 gm of phytosterol *POE is polyoxyethylene *DEA is diethanolamide Oil-filled vesicles were formed using the hot loading method described in Example 1, except that the lipid phase was heated to 70°C and hydrated by the aqueous phase at 60°C.
Hydration to form lipid vesicles was achieved using 20cc syringes in place of the 60cc syringes used in Example 1. After processing to form lipid vesicles, the following results were observed:
Sample A (Brij 56'and avocado oil unsaponifiables) had a fluid consistency.
Upon microscopic examination, many heterogenous, but small vesicles were visible.
After centrifugation at 3500 rpm for 15 minutes, no separation was observed, but a small amount of creaming formed on top of the Sample. Mean particle size of the vesicles, measured by Coulter Counter, was 254 nm.
"Trade Mark Sample B (Brij 72~and avocado oil unsaponifiables) had a lotion-like consistency.
Upon microscopic examination, many heterogenous vesicles were visible. After centrifugation at 3500 rpm for 15 minutes, no separation was observed. Mean particle size of the vesicles, measured by Coulter Counter, was 765 nm.
Sample C (Brij 76~~and avocado oil unsaponifiables) had a fluid consistency.
Upon microscopic examination, very nice small vesicles were visible. After centrifugation at 3500 rpm for 15 minutes, 2 ml of hazy solution separated as infernatant. Mean particle size of the vesicles, measured by Coulter Counter, was 281 run.
Sample D (Brij 9'7~and avocado oil unsaponifiables) had a very fluid consistency.
Upon microscopic examination, both very nice small vesicles and some large vesicles were visible. After centrifugation at 3500 rpm for 15 minutes, no separation was observed, but a small amount of creaming formed on top of the Sample. Mean particle size of the vesicles, measured by Coulter Counter, was 151 nm.
Sample E (Brij 30jand avocado oil unsaponifiables) had a very fluid consistency.
Upon microscopic examination, both very nice small vesicles and some large vesicles were visible. After centrifugation at 3500 rpm for 15 minutes, no separation was observed, but a small amount of creaming formed on top of the Sample. Mean particle size of the vesicles, measured by Coulter Counter, was 348 nm.
Sample F (Brij 92 and avocado oil unsaponifiables) had a fluid consistency.
Upon microscopic examination, nice spherical vesicles were visible. After centrifugation at 3500 rpm for 15 minutes, 1 ml of turbid aqueous solution separated as infernatant.
Mean particle size of the vesicles, measured by Coulter Counter, was 381 nm.
Sample G (Tween 60 and avocado oil unsaponifiables) had a very fluid consistency.
Upon microscopic examination, extremely small homogenous vesicles were visible. After centrifugation at 3500 rpm for 15 minutes, no separation was observed, but a small amount of creaming formed on top of the Sample. Mean particle size of the vesicles, measured by Coulter Counter, was 151 nm.
Sample H (Tween 80 and avocado oil unsaponifiables) had the same consistency and size vesicles as Sample G. After centrifugation at 3500 rpm for 15 minutes, no separation was observed. Mean particle size of the vesicles, measured by Coulter Counter, was 164 nm.
Sample I (Myrj 45 and avocado oil unsaponifiables) had a fluid consistency.
Upon microscopic examination, very nice looking small vesicles were visible. After centrifugation 'Trade Mark at 3500 rpm for 1 ~ minutes, no separation was observed, but the Sample took on a lotion-like consistency. Mean particle size of the vesicles, measured by Coulter Counter, was 310 nm.
Sample J (Mona 150 LWA and avocado oil unsaponifiables) had a creamy ~ consistency. Upon microscopic examination, the vesicles appeared similar to those of Sample I (small and nice looking). After centrifugation at 3500 rpm for 15 minutes, no separation was observed. Mean particle size of the vesicles, measured by Coulter Counter, was 252 nm.
Sample K (Mona 150 LWA and avocado oil unsaponifiables) had a fairly thick, creamy consistency. Upon microscopic examination, nicely shaped heterogenous vesicles were visible. After centrifugation at 3500 rpm for 15 minutes, no separation was observed.
Mean particle size of the vesicles, measured by Coulter Counter, was 644 nm.
1 ~ Sample L (Mona 15-70w and avocado oil unsaponifiables) had the same consistency as Sample K. Upon microscopic examination, the vesicles also appeared similar to those of Sample K, except that they were smaller. After centrifugation at 3500 rpm for 1 S minutes, no separation was observed. Mean particle size of the vesicles, measured by Coulter Counter, was 218 nm.
This Example shows that avocado oil unsaponifiables can be used in combination with a variety of primary amphiphiles, in particular the Tween family of ethoxylated sorbitan J.
fatty acid esters, the Brij family of polyoxyethylene fatty ethers, the Myrj family of polyoxyethylene derivatives of stearic acid, and the Mona family of diethanolamides to form 2~ good lipid vesicles. None of the samples showed birefringence, probably due to the small particle size of the vesicles.
Exam lie 5 In this Example lipid vesicles for use in hair conditioners were formed. The primary amphiphile making up the lipid bilayers consisted of glyceryl distearate in Sample A and polyoxyethylene (8) stearate in Sample B. Stearyl alcohol was added as a secondary amphiphile. The lipid bilayers also contained phytosterol from avocado oil unsaponifiables (supplied by Croda Inc., Parsippany, N.J.). Distearyldimonium chloride was used as a positive charge producing agent.
3~
In the aqueous phase, sodium laurel sulfate (30%) was used as a secondary emulsifier, along with methyldibromo glutaronitrile phenoxyethenol polyquaterniurn 7 as a preservative. Cetyl trimethyl ammonium chloride was used as a positive charge producing agent.
*Trade Mark (% by ght) wei A B Lipid Phase 1.5 0.5 Stearyl Alcohol 2.0 Glyceryl Distearate 1.7 Polyoxyethylene (8) Stearate 3.33 1.0 Avocado Oil Unsaponifiables*
2.5 2.5 Distearyldimonium Chloride Aqueous Phase 0.5 0.5 Sodium Laurel Sulfate 30%
0.1 0.1 Methyldibromo Glutaronitrile Phenoxyethenol Polyquaternium 7 0.1 2.0 Cetyl Trimethyl Ammonium Chloride 88.0 91.7 Deionized Water * 1 gram of Avocado Oil Unsaponifiables contains approximately 0.3 gm of phytosterol The lipid vesicles were hot loaded according to the method described in Example 1.
Sample A was processed using a hydration ratio of 1 part lipid at 80°C
to 9.5 parts aqueous at 70°C. Sample B was processed using a hydration ratio of 1 part lipid at 90°C to 16.5 parts aqueous at 70°C.
After processing to form lipid vesicles, both Samples A and B had a creamy consistency, appropriate for use as a hair conditioner. Upon microscopic examination, the vesicles of both Samples were very good and homogenous.
This Example shows that avocado oil unsaponifiables, which acts both as a structural component of lipid vesicles by supplying phytosterol to the lipid walls, as well as a moisturizing agent by supplying triglycerides to the central cavity can be used along with amphiphiles which also have cosmetic (e.g., moisturizing) properties, such as glyceryl distearate and polyoxyethylene 8 stearate, to form good lipid vesicles suitable for use in cosmetics. Other useful materials (i.e., emulsifiers and preservatives) can also be added to the aqueous portion of the lipid vesicles, such as sodium laurel sulfate (30%) and methyldibromo glutaronitrile phenoxyethenol polyquaternium 7.
xam~le 6 In this Example, lipid vesicles were formed for use in a skin rejuvenating cream.
Polyoxyethylene 8 stearate was used as the primary amphiphile and stearyl alcohol, stearyl alcohol-Ceteareth 20 and cetearyl alcohol-Ceteareth 20 were used as the secondary' amphiphiles making up the lipid bilayers. Avocado oil unsaponifiables was also added to provide phytosterol to the bilayers and triglycerides to the central cavity. A
variety of other moisturizing agents were also added to the lipid phase, such as shark liver oil, petrolatum lanolin-lanolin alcohol, benzoic acid alkyl esters and cetyl acetate-acetylated lanolin alcohol, all of which were encapsulated in the central core of the lipid vesicles.
Tocopherol concentrate (vitamin E) and BHA (butylated hydroxy anisol) were added to the lipid phase as antioxidants.
The aqueous portion of the lipid vesicles contained glycerin (99%) and butylene glycol as humectants, sodium DL2 pyrrolidone 5 carboxylate, aloe vera concentrate, SRF
(skin respiratory factor) and collagen as moisturizers, di sodium EDTA as a chelating agent, and methyldibromo glutaronitrile phenoxyethenol polyquaternium 7 as an antibacterial agent.
by Weight LIPID PHASE
0.5 Shark Liver Oil 0.1 Petrolatum-Lanolin-Lanolin Alcohol 0.5 Benzoic Acid-C12 - 15 Alkyl Esters 0.1 TOCOPHEROL Concentrate (Vitamin E) 1.5 Copolyol 3.0 Stearyl Alcohol - Ceteareth - 20 0.~ Stearyl Alcohol 1.0 Cetearyl Alcohol - Ceteareth -1.7 Polyoxyethylene (8) Stearate 1.0 Avocado Oil Unsaponifiables 0.04 Fragrance 0.1 BHA
1.0 Cetyl Acetate - Acetylated Lanolin Alcohol AQUEOUS PHASE
4.0 Glycerin 99%
6.0 Butylene Glycol 1.0 Sodium DL2 Pyrrolidone S - Carboxylate 0.2 Aloe Vera Concentrate 0.1 Di Sodium EDTA
0.1 Collagen 0.2 Methyldibromo Glutaronitrile Phenoxyethenol Polyquaternium 7 0.05 SRF Powder 77.31 Deionized Water The lipid vesicles were hot loaded according to the method described in Example I .
A hydration ratio of 1 part lipid at 80°C to 16.5 parts aqueous at 70°C was used. After processing to form lipid vesicles, the sample had a creamy consistency, appropriate for use as a skin rejuvenating cream. Upon microscopic examination, the vesicles were very good S looking and homogenous.
This Example shows that a variety of amphiphiles which have cosmetic properties (i.e., moisturizers) can be used in combination with avocado oil unsaponifiables to form the lipid bilayers and to fill the central cavity of vesicles for use in skin creams. Avocado oil unsaponifiables provides the advantage of acting both as a good structural component of vesicles by providing phytosterol to the lipid bilayers, as well as a moisturizing agent by providing triglycerides to the central cavity.
Examnlg 7 In this Example, lactic acid carrying lipid vesicles were formed for use in .dermatologicals. The lipid bilayers of the vesicles were made up of glycerol distearate as the primary amphiphile, polyoxyethylene 10 stearyl ether, stearyl alcohol-Ceteareth 20, cetearyl alcohol-Ceteareth 20 and stearyl alcohol as secondary amphiphiles, and phytosterol supplied by avocado oil unsaponifiables. Other materials included in the lipid phase to be encapsulated in the central core of the vesicles were lactic acid (88%) (a dead skin cell remover), and cetyl acetate-acetylated lanolin alcohol, alkyl lactate and octyl hydroxystearate (skin moisturizers).
The aqueous phase included methyl paraben as a preservative, Bronopol (methyldibromo glutaronitrile phenoxyethenol polyquaternium 7) and propyl paraben as antibacterials, glycerin (96%) as a humectant, and Polysorbate 80~(polyoxyethylene 20 sorbitan monooleate) as a secondary emulsifier.
by Weight LIPID PHASE
5.7 Lactic Acid 88%
1.4 Polyoxyethylene 10 Stearyl Ether 3.3 Avocado Oil Unsaponifiables 6.3 Octyl Hydroxystearate 2.8 Glycerol Distearate 3.0 Stearyl Alcohol - Ceteareth 20 1.0 Cetearyl Alcohol - Ceteareth 20 1.0 Stearyl Alcohol 1.0 Cetyl Acetate and Acetylated Lanolin Alcohol 1.5 C 12-15 Alkyl Lactate "Trade Mark AQUEOUS PHASE
0.2 Methyl Paraben 4.0 Glycerin 96%
S 1.24 Sodium Hydroxide 0.03 Propyl Paraben 0.10 Sodium Chloride f Y_ 0.75 Polysorbate 80 0.05 Bronopol 4.0 Silicone Emulsion 0.2 Fragrance 62.93 Deionized Water The lipid vesicles were hot loaded according to the method described in Example 1.
A hydration ratio of 1 part lipid at 70°C to 16.5 parts aqueous at 60°C was used. After processing, the sample had a creamy consistency, appropriate for use in dermatological preparations. Upon microscopic examination, the vesicles were very good looking and homogenous.
This Example shows that avocado oil unsaponifiables can be used with amphiphiles and other materials having dermatological properties to form lipid vesicles for use in dermatologicals. Avocado oil unsaponifiables provides the advantage of acting both as a source of phytosterol for the lipid bilayers, as well as a source of triglycerides (moisturizing agent) to be encapsulated in the central cavity of the vesicles.
The foregoing Examples are merely illustrative and those skilled in the art may be able to determine other materials and methods which accomplish the same results. Such other materials and methods are included within the following claims.
*Trade Mark
Claims (22)
1. A paucilamellar lipid vesicle having 2-10 bilayers surrounding an amorphous oil-filled central cavity comprising an oil filling, a portion of the oil filling of said oil-filled central cavity being supplied by avocado oil unsaponifiables, wherein each of said bilayers contains at least one non-phospholipid amphiphile selected from the group consisting of polyoxyethylene fatty esters, polyoxyethylene fatty acid ethers, diethanolamides, long chain acyl hexosamides, long chain acyl amino acid amides, long chain acyl amides, polyoxyethylene derivatives of fatty acid esters having 10-oxyethylene groups, POE (20) sorbitan mono- or trioletate, polyoxyethylene glyceryl monostearate with 1-10 oxyethylene groups, and glycerol monostearate as the primary lipid in said bilayers, and phytosterol supplied by said avocado oil unsaponifiables as a modulator in said bilayers.
2. The paucilamellar vesicle of claim 1, wherein said polyoxyethylene fatty esters have the formula R1-COO(C2H4O)n H
where R1 is lauric, myristic, cetyl, stearic, or oleic acid, or their derivatives and n=2-10;
said polyoxyethylene fatty acid ethers have the formula R2-CO(C2H4)m H
where R2 is lauric, myristic or cetyl acids or their derivatives, single or double unsaturated octadecyl acids or their derivatives, or double unsaturated eicodienoic acids or their derivatives and m ranges from 2-4;
said diethanolamides have the formula (HOCH2-CH2)2NCO-R3 where R3 is caprylic, lauric, myristic, or linoleic acids or their derivatives;
said long chain acyl hexosamides have the formula R4-NHCO-(CH2)b-CH3 where b ranges from 10-18 and R4 is a sugar molecule selected from a group consisting of glucosamine, galactosamine, and N-methylglucamine;
said long chain acyl amino acid amides have the formula R5-CH(COOH)-NHCO-(CH2)c-CH3 where c ranges from 10-18 and R5 is an amino acid side chain;
said long chain acyl amides have the formula HOOC-(CH2)d-N(CH3)-(CH2)3-NCHO-R6 where R6 is an acyl chain having 10-20 carbons and not more than two unsaturations, and d ranges from 1-3.
where R1 is lauric, myristic, cetyl, stearic, or oleic acid, or their derivatives and n=2-10;
said polyoxyethylene fatty acid ethers have the formula R2-CO(C2H4)m H
where R2 is lauric, myristic or cetyl acids or their derivatives, single or double unsaturated octadecyl acids or their derivatives, or double unsaturated eicodienoic acids or their derivatives and m ranges from 2-4;
said diethanolamides have the formula (HOCH2-CH2)2NCO-R3 where R3 is caprylic, lauric, myristic, or linoleic acids or their derivatives;
said long chain acyl hexosamides have the formula R4-NHCO-(CH2)b-CH3 where b ranges from 10-18 and R4 is a sugar molecule selected from a group consisting of glucosamine, galactosamine, and N-methylglucamine;
said long chain acyl amino acid amides have the formula R5-CH(COOH)-NHCO-(CH2)c-CH3 where c ranges from 10-18 and R5 is an amino acid side chain;
said long chain acyl amides have the formula HOOC-(CH2)d-N(CH3)-(CH2)3-NCHO-R6 where R6 is an acyl chain having 10-20 carbons and not more than two unsaturations, and d ranges from 1-3.
3. The paucilamellar vesicle of claim 1 or 2, wherein said bilayers further comprise a second material selected from the group consisting of phospholipids, glycolipids, and mixtures thereof.
4. The paucilamellar lipid vesicle of any one of claims 1 to 3, wherein said primary non-phospholipid amphiphile is selected from the group consisting of betaines and anionic sarcosinamides.
5. The paucilamellar lipid vesicle of claim 1, wherein said primary non-phospholipid amphiphile is selected from the group consisting of C12-C18 fatty alcohols, C12-C18 glycol monoesters, C12-C18 glyceryl mono- and diesters,, propylene glycol stearate, sucrose distearate, and mixtures thereof; and wherein said bilayers further comprise a second non-phospholipid amphiphile selected from the group consisting of quaternary dimethyldiacyl amines, polyoxyethylene acyl alcohols, polyglycerols, sorbitan fatty acids esters, polyoxyethylene derivatives of sorbitan fatty acid esters, fatty acids and their salts, and mixtures thereof.
6. The paucilamellar lipid vesicle of claim 5, wherein said primary non-phospholipid amphiphile is selected from the group consisting of C16-C18 fatty alcohols, glycol stearate, glyceryl mono- and distearate, glyceryl dilaurate, and mixtures thereof.
7. The paucilamellar lipid vesicle of claim 5, where said second non-phospholipid amphiphile is selected from the group consisting of stearyl alcohol, polyoxyethylene fatty alcohols, polyoxyethylene derivatives of sorbitan fatty acid esters having 10-20 oxyethylene groups, and mixtures thereof; wherein the fatty alcohol or fatty acid groups of the polyoxyethylene fatty alcohols and the polyoxyethylene derivatives of sorbitan fatty acid esters are selected from the group consisting of radicals of palmetic acid, stearic acid, lauric acid, and oleic acid, and mixtures thereof.
8. A method of forming a paucilamellar lipid vesicle having 2-10 lipid bilayers surrounding an oil-filled amorphous central cavity, said method comprising the steps of:
A. preparing a lipophilic phase containing at least one non-phospholipid amphiphile selcted from the group consisting of polyoxyethylene fatty esters, polyoxyethylene fatty acid ethers, diethanolamides, long chain acyl hexosamides, long chain acyl amino acid amides, long chain acyl amides, polyoxyethylene derivatives of fatty acid esters having 10-20 oxyethylene groups, POE (20) sorbitan mono-or trioletate, polyoxyethylene glyceryl monostearate with 1-10 oxyethylene groups, and glycerol monostearate as the primary lipid to be incorporated into said bilayers;
B. blending said lipophilic phase with avocado oil unsaponifiables and any other oily material to be encapsulated into said vesicle to form a lipid phase;
C. preparing an aqueous phase of an aqueous-based hydrating agent and any aqueous soluble material to be encapsulated into said vesicle; and D. shear mixing said lipid phase with said aqueous phase to form said lipid vesicle, without the formation of a separable lamellar phase, whereby said avocado oil unsaponifiables partition so that phytosterol from said avocado oil unsaponifiables is incorporated into the bilayers of said lipid vesicle and the remaining components of said avocado oil unsaponifiables are entrapped in the amorphous central cavity of said lipid vesicle.
A. preparing a lipophilic phase containing at least one non-phospholipid amphiphile selcted from the group consisting of polyoxyethylene fatty esters, polyoxyethylene fatty acid ethers, diethanolamides, long chain acyl hexosamides, long chain acyl amino acid amides, long chain acyl amides, polyoxyethylene derivatives of fatty acid esters having 10-20 oxyethylene groups, POE (20) sorbitan mono-or trioletate, polyoxyethylene glyceryl monostearate with 1-10 oxyethylene groups, and glycerol monostearate as the primary lipid to be incorporated into said bilayers;
B. blending said lipophilic phase with avocado oil unsaponifiables and any other oily material to be encapsulated into said vesicle to form a lipid phase;
C. preparing an aqueous phase of an aqueous-based hydrating agent and any aqueous soluble material to be encapsulated into said vesicle; and D. shear mixing said lipid phase with said aqueous phase to form said lipid vesicle, without the formation of a separable lamellar phase, whereby said avocado oil unsaponifiables partition so that phytosterol from said avocado oil unsaponifiables is incorporated into the bilayers of said lipid vesicle and the remaining components of said avocado oil unsaponifiables are entrapped in the amorphous central cavity of said lipid vesicle.
9. The method of claim 8, wherein said polyoxyethylene fatty esters have the formula R1-COO(C2H4O)n H
where R1 is lauric, myristic, cetyl, stearic, or oleic acid, or their derivatives and n=2-10;
said polyoxyethylene fatty acid ethers have the formula R2-CO(C2H4)m H
where R2 is lauric, myristic or cetyl acids or their derivatives, single or double unsaturated octadecyl acids or their derivatives, or double unsaturated eicodienoic acids or their derivatives and m ranges from 2-4;
said diethanolamides have the formula (HOCH2-CH2)2NCO-R3 where R3 is caprylic, lauric, myristic, or linoleic acids or their derivatives;
said long chain acyl hexosamides have the formula R4-NHCO-(CH2)b-CH3 where b ranges from 10-18 and R4 is a sugar molecule selected from a group consisting of glucosamine, galactosamine, and N-methylglucamine; and said long chain acyl amino acid amides have the formula R5-CH(COOH)-NHCO-(CH2)c-CH3 where c ranges from 10-18 and R5 is an amino acid side chain;
said long chain acyl amides have the formula HOOC-(CH2)d-N(CH3)-(CH2)3-NCHO-R6 where R6 is an acyl chain having 10-20 carbons and not more than two unsaturations, and d ranges from 1-3.
where R1 is lauric, myristic, cetyl, stearic, or oleic acid, or their derivatives and n=2-10;
said polyoxyethylene fatty acid ethers have the formula R2-CO(C2H4)m H
where R2 is lauric, myristic or cetyl acids or their derivatives, single or double unsaturated octadecyl acids or their derivatives, or double unsaturated eicodienoic acids or their derivatives and m ranges from 2-4;
said diethanolamides have the formula (HOCH2-CH2)2NCO-R3 where R3 is caprylic, lauric, myristic, or linoleic acids or their derivatives;
said long chain acyl hexosamides have the formula R4-NHCO-(CH2)b-CH3 where b ranges from 10-18 and R4 is a sugar molecule selected from a group consisting of glucosamine, galactosamine, and N-methylglucamine; and said long chain acyl amino acid amides have the formula R5-CH(COOH)-NHCO-(CH2)c-CH3 where c ranges from 10-18 and R5 is an amino acid side chain;
said long chain acyl amides have the formula HOOC-(CH2)d-N(CH3)-(CH2)3-NCHO-R6 where R6 is an acyl chain having 10-20 carbons and not more than two unsaturations, and d ranges from 1-3.
10. The method of claim 8 or 9, wherein said bilayers further comprise a second material selected from the group consisting of phospholipids, glycolipids, and mixtures thereof.
11. The method of any one of claims 8 to 10, wherein said primary non-phospholipid amphiphile is selected from the group consisting of betaines and anionic sarcosinamides.
12. The method of claim 8, wherein said primary non-phospholipid amphiphile is selected from the group consisting of C12-C18 fatty alcohols, C12-C18 glycol monoesters, C12-C18 glyceryl mono- and diesters, propylene glycol stearate, sucrose distearate, and mixtures thereof; and wherein said bilayers further comprise a second non-phospholipid amphiphile selected from the group consisting of quaternary dimethyldiacyl amines, polyoxyethylene acyl alcohols, polyglycerols, sorbitan fatty acid esters, polyoxyethylene derivatives of sorbitan fatty acid esters, fatty acids and their salts, and mixtures thereof.
13. The method of claim 12, wherein said primary non-phospholipid amphiphile is selected from the group consisting of C16,-C18 fatty alcohols, glycol stearate, glyceryl mono- and distearate, glyceryl dilaurate, and mixtures thereof.
14. The method of claim 12 wherein said second non-phospholipid amphiphile is selected from the group consisting of stearyl alcohol, polyoxyethylene fatty alcohols, polyoxyethylene derivatives of sorbitan fatty acid esters having 10-oxyethylene groups, and mixtures thereof; wherein the fatty alcohol or fatty acid groups of the polyoxyethylene fatty alcohols and the polyoxyethylene derivatives of sorbitan fatty acid esters are selected from the group consisting of radicals of palmetic acid, stearic acid, lauric acid, and oleic acid, and mixtures thereof.
15. A paucilamellar lipid vesicle having 2-10 bilayers surrounding an amorphous oil-filled central cavity, wherein each of said bilayers contains at least one non-phospholipid amphiphile selected from the group consisting of polyoxyethylene fatty esters, polyoxyethylene fatty acid ethers, diethanolamides, long chain acyl hexosamides, long chain acyl amino acid amides, long chain acyl amides, POE (20) sorbitan mono- or trioletate, and glycerol monostearate as the primary lipid in said bilayers and phytosterol supplied by avocado oil unsaponifiables, said avocado oil unsaponifiables partitioning in manufacture of said paucilamellar lipid vesicles, so that a sufficient amount of the phytosterol from said avocado oil unsaponifiables goes into said bilayers so as to stabilize said bilayers and the remainder of said avocado oil unsaponifiables goes into said amorphous central cavity.
16. The paucilamellar vesicle of claim 15, wherein said polyoxyethylene fatty esters have the formula R1-COO(C2H4O)n H
where R1 is lauric, myristic, cetyl, stearic, or oleic acid, and n 32 2-10;
said polyoxyethylene fatty acid ethers have the formula R2 -CO(C2H4)m H
where R2 is lauric, myristic or cetyl acids, single or double unsaturated octadecyl acids, or double unsaturated eicodienoic acids and m ranges from 2-4;
said diethanolamides have the formula (HOCH2-CH2)2 NCO-R3 where R3 is caprylic, lauric, myristic, or linoleic acids;
said long chain acyl hexosamides have the formula R4 -NHCO-(CH2)b-CH3 where b ranges from 10-18 and R4 is a sugar molecule selected from a group consisting of glucosamine, galactosamine, and N-methylglucamine;
said long chain acyl amino acid amides have the formula R5-CH(COOH)-NHCO-(CH2)c-CH3 where c ranges from 10-18 and R5 is an amino acid side chain;
said long chain acyl amides have the formula HOOC-(CH2)d-N(CH3)-(CH2)3-NCHO-R6 where R6 is an acyl chain having 10-20 carbons and not more than two unsaturations, and d ranges from 1-3.
where R1 is lauric, myristic, cetyl, stearic, or oleic acid, and n 32 2-10;
said polyoxyethylene fatty acid ethers have the formula R2 -CO(C2H4)m H
where R2 is lauric, myristic or cetyl acids, single or double unsaturated octadecyl acids, or double unsaturated eicodienoic acids and m ranges from 2-4;
said diethanolamides have the formula (HOCH2-CH2)2 NCO-R3 where R3 is caprylic, lauric, myristic, or linoleic acids;
said long chain acyl hexosamides have the formula R4 -NHCO-(CH2)b-CH3 where b ranges from 10-18 and R4 is a sugar molecule selected from a group consisting of glucosamine, galactosamine, and N-methylglucamine;
said long chain acyl amino acid amides have the formula R5-CH(COOH)-NHCO-(CH2)c-CH3 where c ranges from 10-18 and R5 is an amino acid side chain;
said long chain acyl amides have the formula HOOC-(CH2)d-N(CH3)-(CH2)3-NCHO-R6 where R6 is an acyl chain having 10-20 carbons and not more than two unsaturations, and d ranges from 1-3.
17. The paucilamellar vesicle of claim 16, wherein said bilayers further comprise a second material selected from the group consisting of phospholipids, glycolipids, and mixtures thereof.
18. The paucilamellar lipid vesicle of claim 15, wherein said primary non-phospholipid amphiphile is selected from the group consisting of betaines and anionic sarcosinamides.
19. The paucilamellar lipid vesicle of claim 15, wherein said primary non-phospholipid amphiphile is selected from the group consisting of C12-C18 fatty alcohols, C12 -C18 glycol monoesters, C12-C18 glyceryl mono- and diesters, propylene glycol stearate, sucrose distearate, and mixtures thereof; and wherein said bilayers further comprise a second non-phospholipid amphiphile selected from the group consisting of quaternary dimethyldiacyl amines, polyoxyethylene acyl alcohols, polyglycerols, sorbitan fatty acid esters, polyoxyethylene derivatives of sorbitan fatty acid esters, fatty acids and their salts, and mixtures thereof.
20. The paucilamellar lipid vesicle of claim 19, wherein said primary non-phospholipid amphiphile is selected from the group consisting of C16-C18 fatty alcohols, glycol stearate, glyceryl mono- and distearate, glyceryl dilaurate, and mixtures thereof.
21. The paucilamellar lipid vesicle of claim 19, wherein said second non-phospholipid amphiphile is selected from the group consisting of stearyl alcohol, polyoxyethylene fatty alcohols, polyoxyethylene derivatives of sorbitan fatty acid esters having 10-20 oxyethylene groups, and mixtures thereof; wherein the fatty alcohol or fatty acid groups of the polyoxyethylene fatty alcohols and the polyoxyethylene derivatives of sorbitan fatty acid esters are selected from the group consisting of radicals of palmitic acid, stearic acid, lauric acid, and oleic acid, and mixtures thereof.
22. The paucilamellar lipid vesicle of any one of claims 1 to 7 and 15 to 21, wherein said avocado oil unsaponifiables are provided in an amount of 20 to 65%
by weight of the total weight of lipids in said paucilamellar lipid vesicle.
by weight of the total weight of lipids in said paucilamellar lipid vesicle.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16754793A | 1993-12-15 | 1993-12-15 | |
US08/167,547 | 1993-12-15 | ||
PCT/US1994/012158 WO1995016436A1 (en) | 1993-12-15 | 1994-10-25 | Lipid vesicles containing avocado oil unsaponifiables |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2177696A1 CA2177696A1 (en) | 1995-06-22 |
CA2177696C true CA2177696C (en) | 2003-03-11 |
Family
ID=22607816
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002177696A Expired - Lifetime CA2177696C (en) | 1993-12-15 | 1994-10-25 | Lipid vesicles containing avocado oil unsaponifiables |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0734250A1 (en) |
JP (1) | JPH09510432A (en) |
AU (1) | AU693488B2 (en) |
CA (1) | CA2177696C (en) |
WO (1) | WO1995016436A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU3688395A (en) * | 1994-09-27 | 1996-04-19 | Rijksuniversiteit Leiden | Phospholipid- and cholesterol-free aqueous composition for opical application to the skin |
US6991781B2 (en) * | 2001-01-17 | 2006-01-31 | The Procter & Gamble Company | Delivery of reactive agents via bi-layer structures for use in shelf-stable products |
DE60137229D1 (en) * | 2001-10-22 | 2009-02-12 | Viroblock Sa | Non-phospholipid vesicles (npLV) and their use in cosmetic, therapeutic and prophylactic applications |
US7252830B2 (en) * | 2003-10-06 | 2007-08-07 | The Gillette Company | Moisturizing compositions |
CA2675745A1 (en) * | 2007-01-18 | 2008-07-24 | Mark A. Pinsky | Materials and methods for delivering antioxidants into the skin |
GB201017113D0 (en) | 2010-10-11 | 2010-11-24 | Chowdhury Dewan F H | Surfactant vesicles |
GR1008481B (en) * | 2013-12-05 | 2015-05-12 | Συμβουλοι Αναπτυξης Πωλησεων Επε, | Method for the confinement of plant oils (olive oil) with use of specific edible liposomes without phospholipids- application of said method in food, charcuterie, dairy products and fish preparations |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4891208A (en) * | 1985-04-10 | 1990-01-02 | The Liposome Company, Inc. | Steroidal liposomes |
US4830858A (en) * | 1985-02-11 | 1989-05-16 | E. R. Squibb & Sons, Inc. | Spray-drying method for preparing liposomes and products produced thereby |
US5032457A (en) * | 1988-03-03 | 1991-07-16 | Micro Vesicular Systems, Inc. | Paucilamellar lipid vesicles using charge-localized, single chain, nonphospholipid surfactants |
-
1994
- 1994-10-25 WO PCT/US1994/012158 patent/WO1995016436A1/en not_active Application Discontinuation
- 1994-10-25 CA CA002177696A patent/CA2177696C/en not_active Expired - Lifetime
- 1994-10-25 EP EP95901030A patent/EP0734250A1/en not_active Withdrawn
- 1994-10-25 JP JP7516744A patent/JPH09510432A/en active Pending
- 1994-10-25 AU AU10418/95A patent/AU693488B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
EP0734250A1 (en) | 1996-10-02 |
WO1995016436A1 (en) | 1995-06-22 |
AU1041895A (en) | 1995-07-03 |
JPH09510432A (en) | 1997-10-21 |
CA2177696A1 (en) | 1995-06-22 |
AU693488B2 (en) | 1998-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5643600A (en) | Lipid vesicles containing avocado oil unsaponifiables | |
CA2175472C (en) | Propylene glycol stearate vesicles | |
JP2595478B2 (en) | Cosmetic composition acting simultaneously on surface layer and deep layer of skin and use thereof | |
US5256422A (en) | Lipid vesicle containing water-in-oil emulsions | |
CA2175471C (en) | Sucrose distearate lipid vesicles | |
KR101052493B1 (en) | Blessicle dispersions and cosmetics containing the same | |
JPH07502196A (en) | Blended lipid vesicles | |
US5268180A (en) | Cosmetic pharmaceutical or foodstuff composition comprising an aqueous dispersion of lipidic vesicles | |
JPH044284B2 (en) | ||
JPH06507185A (en) | Cosmetic or pharmaceutical compositions containing dispersions of lipid vesicles, methods for producing the dispersions, and dispersions of lipid vesicles | |
NL8720192A (en) | A METHOD FOR FACILITATING THE FORMATION OF A WATER PHASE DISTRIBUTED LIPID GLASS AND FOR IMPROVING ITS STABILITY AND COATING AMOUNT AND CORRESPONDING DISPERSIONS. | |
JP4820002B2 (en) | Glucosid pouch lamella vesicle | |
CA2177696C (en) | Lipid vesicles containing avocado oil unsaponifiables | |
CA2108039C (en) | Lipid vesicle containing water-in-oil emulsions | |
Stanzl | Liposomes | |
EP1239811A2 (en) | Compositions comprising fluid petrolatum and methods for the use thereof | |
Stanzl | Dragoco Gerberding & Co. AG, Holzminden, Germany |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20141027 |